Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Eledon Pharmaceuticals, Inc. announced that CEO David-Alexandre C. Gros will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET. Interested participants can register for the presentation webcast here. A replay will be available on the company’s website after the live session. Eledon is developing innovative therapies targeting the CD40 Ligand pathway, including its lead compound, tegoprubart, for organ and cell transplants, autoimmune diseases, and ALS.
Eledon Pharmaceuticals is focusing resources on advancing tegoprubart for kidney transplantation, with ongoing enrollment in a Phase 1b trial and plans for a Phase 2 BESTOW trial set to begin in mid-2023. The company deprioritized its IgA Nephropathy program and discontinued its islet cell transplantation efforts to concentrate on kidney transplant opportunities. Eledon has sufficient financial resources to support its operations into 2024. Initial data from the ongoing trials are expected to be released at the World Congress of Nephrology in March 2023.
Eledon Pharmaceuticals announced on December 20, 2022, that the Critical Path Institute's Transplant Therapeutic Consortium received EMA qualification for the iBox Scoring System as a secondary efficacy endpoint in kidney transplant trials. This novel endpoint aims to enhance immunosuppressive therapy (IST) applications, predicting graft failure using various biomarkers, including renal function measures and immunologic responses. CEO David Alexandre C. Gros expressed commitment to integrating the iBox system into future trials for tegoprubart, their lead drug targeting allograft rejection.
Eledon Pharmaceuticals reported significant advancements in its clinical trials and regulatory approvals for tegoprubart, aimed at preventing organ rejection in kidney transplant patients and treating IgA Nephropathy (IgAN). The FDA cleared IND applications for both indications, allowing for Phase 2 trials to commence. The company has dosed initial patients in an ex-U.S. Phase 1b trial and plans to expand globally, including China in 2023. Despite a net loss of $10.5 million in Q3 2022, Eledon maintains adequate financial resources with $65.9 million in cash, enough to sustain operations into 2024.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its third-quarter financial results for the period ended September 30, 2022, on November 14, 2022, after market close. A conference call and webcast to discuss these results will take place at 4:30 PM ET on the same day. Eledon focuses on developing treatments targeting the CD40L pathway, with its lead candidate being tegoprubart, intended for organ transplant recipients, autoimmune disease patients, and those with ALS. The event will be archived on the company's website for one year.
Eledon Pharmaceuticals (NASDAQ: ELDN) announces its participation in two significant medical conferences this November. At the American Society of Nephrology's Kidney Week 2022 (November 3-6 in Orlando, FL), Eledon will present two posters focusing on the safety and efficacy of tegoprubart in treating IgA nephropathy and its potential for ALS. Additionally, a poster on tegoprubart's safety profile in ALS will be showcased at the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) conference (November 1-3 in Clearwater Beach, FL). Eledon specializes in treatments for autoimmune diseases and organ transplant needs.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced participation in two upcoming conferences. On October 6, Steven Perrin, Ph.D., will engage in a panel discussion on ALS treatment at the Cantor Neurology & Psychiatry Conference. On October 7, Jeff Bornstein, M.D., will present on the safety and efficacy of tegoprubart for ALS patients at the ALS One 5th Annual ALS Research Symposium. Both presentations are exclusive to registered attendees. Eledon focuses on developing therapies targeting the CD40L pathway for organ transplant, autoimmune diseases, and ALS.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:00 p.m. ET in New York City. Interested parties can register for the webcast here. A replay will be available afterward on the company’s website.
Eledon specializes in developing treatments targeting the CD40 Ligand pathway for transplant patients and those with autoimmune diseases.
Eledon Pharmaceuticals has announced FDA clearance of its IND application for tegoprubart, aimed at treating IgA Nephropathy (IgAN). The Phase 2a clinical trial, now active in 10 countries including the U.S., will evaluate safety and efficacy in patients with severe proteinuria. The study's primary endpoint focuses on changes in urine protein levels after 24 weeks. Currently, IgAN affects around 150,000 Americans, underscoring the urgency for effective treatments amid limitations of standard therapies.
Eledon Pharmaceuticals, listed on NASDAQ as ELDN, announced its participation in two investor conferences. The first event is a fireside chat at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:00 p.m. ET. The second event is a presentation at the H.C. Wainwright 24th Annual Global Investment Conference, available on-demand from September 12, 2022, at 7:00 a.m. ET. Webcast replays will be accessible on the company's website. Eledon focuses on developing treatments targeting the CD40 Ligand pathway, with its lead candidate being tegoprubart.